



CAPLIN POINT LABORATORIES LTD.

CIN : L24231TN1990PLC019053

Regd. Off. : "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905
Fax : +91 44 28154952 E-mail : info@caplinpoint.net Website : www.caplinpoint.net

10.05.2017

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB : AUDITED FINANCIAL RESULTS FOR THE QUARTER /YEAR ENDED MARCH 31,2017

The Board of Directors at their Meeting held today, May 10,2017, have approved the Stand alone and Consolidated Audited Financial Results for the quarter/year ended March 31,2017 and noted the Auditors Report with the unmodified opinion and the same is enclosed herewith.

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, a declaration with respect to Auditors Report with unmodified opinion is enclosed herewith.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosure : As Above

Unit I : No: 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: +91 413 2674046 / 4047

Unit II : No.19, Chinnapuliur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District. Pincode - 601 201. Ph.: +91 44 27900901

Unit III : KHASRA No.435,Village Suraj Majra, N.H. No.21,Baddi, Teh. Nalagarh, District Solan, Himachal Pradesh – 173205. Ph.: +91 1795 245512

Unit IV: Survey No.: 895 & 897, Gurusvarajakandigai, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District, Pincode – 601 201.

Ph.: +9197884 59333/69333



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNASAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

INDEPENDENT AUDITOR'S REPORT ON STANDALONE FINANCIAL RESULTS OF CAPLIN POINT LABORATORIES LIMITED, CHENNAI FOR QUARTER ENDED MARCH 31 2017 AND YEAR ENDED MARCH 31, 2017.

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED, CHENNAI

1. We have audited the accompanying statements of Standalone financial results of **Caplin Point Laboratories Limited** ("the company" for the quarter ended March 31, 2017 and Financial Year ended March 31, 2017, ("the statements") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company Management and approved by the Board of Directors, has been prepared on the basis of the related standalone Financial Statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.
2. We conducted our audit in accordance with the auditing standards issued by the Institute of Chartered Accounts of India. . Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the statements. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant estimates made by management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
3. In our opinion and to the best of our information and according to the explanations given to us the statements:
 - i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and



- ii. gives a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India, of the Profit and other financial information of the Company for the quarter ended 31/03/2017 as well for the Financial Year ended March, 2017.

For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 004915S /S200036

B. Ramakrishnan

B. Ramakrishnan
Partner
(Membership No. 201023)



Place: Chennai

Date: 10/05/2017

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2017

Part I	Particulars	Quarter Ended			Year ended	9 Months period and Financial Year ended
		31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
		(1)	(2)	(3)	(4)	(5)
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		Rs. In Lakhs				
1	Income					
	a. Net Sales/ income from operations (Net of Excise Duty)	9,535.31	8,767.44	7,719.55	34,154.94	22,704.36
	b. Foreign Exchange Fluctuation Gain	238.10	68.90	-	336.29	-
	c. Share of profits in LLP	(149.35)	94.86	144.58	281.14	424.86
	d. Total	9,624.06	8,931.20	7,864.13	34,772.37	23,129.22
2	Expenditure					
	a. Cost of materials consumed	1,688.82	1,318.97	1,838.94	6,447.19	3,897.53
	b. Purchase of Stock-in-Trade	2,298.73	2,630.97	2,394.63	9,734.11	7,806.63
	c. Change in inventories of Finished Goods, work in progress and stock in trade	140.16	(134.75)	(331.97)	12.40	(30.82)
	d. Employees benefit expenses	781.84	851.86	698.07	2,965.05	1,812.99
	e. Depreciation & Amortisation Expenses	503.06	297.25	255.96	1,325.99	729.91
	f. Foreign Exchange Fluctuation Loss	-	-	35.54	-	321.83
	g. Other Expenditure	1,375.73	1,779.31	1,262.42	5,555.31	3,089.68
	h. Total Expenses	6,788.34	6,743.61	6,153.60	26,040.05	17,627.75
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	2,835.72	2,187.59	1,710.53	8,732.32	5,501.47
4	Other Income	180.63	147.53	153.05	621.77	347.32
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	3,016.34	2,335.12	1,863.57	9,354.09	5,848.79
6	Finance cost	3.47	1.84	2.90	12.75	10.82
7	Profit(+)/Loss(-) before Tax (5-6)	3,012.87	2,333.28	1,860.67	9,341.34	5,837.97
8	Provision for Taxation	608.45	450.46	361.05	1,937.43	1,264.71
	Provision for Taxation - earlier years		-	-		
	Deferred Tax Provision	649.50	112.92	207.90	752.54	264.11
	Mat Credit Entitlement	(434.95)	-	(223.41)	(434.95)	(223.41)
9	Net Profit(+)/Loss(-) for the period (7-8)	2,189.87	1,769.90	1,515.13	7,086.32	4,532.56
10	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs Rs 2/- each wef 20 Oct 2016)	1,511.53	1,511.00	1,511.00	1,511.53	1,511.00
11	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				18,070.07	10,929.47
12	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 10/- per Equity share (prior to sub division of shares)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)			10.03		29.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)			10.03		29.99
	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 2/- per Equity share (post sub division of shares)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.90	2.34	2.01	9.38	5.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.90	2.34	2.01	9.38	5.99



Lohan

Part II		Select information for the quarter ended 31st March 2017		
		"Mar 2017	"Dec 2016	"Mar 2016
A	PARTICULARS OF SHARE HOLDING			
13	Public Shareholding			
	- Number of Shares	23382985	23356235	4863247
	- Percentage of Shareholding	30.94%	30.91%	32.19%
14	Promoters and promoter group Shareholding			
	a) Pledged/Encumbered			
	- Number of Shares	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)			
	- Percentage of shares (as a % of the total share capital of the company)			
	b) Non-encumbered			
	- Number of Shares	52193765	52193765	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	69.06%	69.09%	67.81%

B	Particulars	3 months ended 31-03-2017
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	4
	Received during the quarter	164
	Disposed of during the quarter	166
	Remaining unresolved at the end of the quarter	2



Ludhan

STATEMENT OF ASSETS AND LIABILITIES

Particulars	STANDALONE	
	As at 31/03/2017	As at 31/03/2016
	Rs In Lakhs	Rs. In lakhs
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share Capital	1511.53	1,511.00
Reserves & Surplus	18443.47	11,302.85
TOTAL SHARE HOLDERS FUNDS	19955.00	12,813.85
Minority Interest		
Non-Current Liabilities		
Long-Term Borrowings	47.51	73.08
Deferred Tax Liabilities (Net)	1886.00	1,133.46
Long-Term Provisions	98.19	162.80
Total Non Current Assets	2031.70	1,369.34
Current Liabilities		
Short-Term Borrowings	-	-
Trade Payables	6600.55	5,147.40
Other Current Liabilities	2937.43	6,037.38
Short-Term Provisions	171.56	892.04
Total Current Liabilities	9709.54	12,076.82
TOTAL	31696.24	26,260.01
ASSETS		
Non-Current Assets		
Fixed Assets		
(i) Tangible Assets	15044.76	14,215.06
(ii) Intangible Assets	130.30	60.22
(iii) Capital Work-in-Progress	341.52	23.20
Non-Current Investments	1447.42	143.10
Long-Term Loans and Advances	833.80	336.55
Total Non Current Assets	17797.80	14,778.13
Current Assets		
Current Investment	420.00	-
Inventories	2229.49	1,789.77
Trade Receivables	320.59	680.27
Cash and Cash Equivalents	7665.79	6,476.72
Short-Term Loans and Advances	2999.55	2,287.64
Other Current Assets	263.02	247.48
Total Current Assets	13898.44	11,481.88
Total	31696.24	26,260.01



S. S.


Notes :

- 1) The Financial results of the company for the Year ended 31-03-2017 which have been audited by the statutory auditors have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 10-05-2017.
- 2) The Board of Directors at their meeting held on 10-05-2017, had recommended a final dividend of 75%, i.e Rs 1.50 paise per equity share of Rs 2/- each.
- 3) The Figures for the Quarter Ended 31 March 2017 are balancing figures between the audited figures in respect of the full financial year and the year-to-date figures upto the third Quarter of the Financial year.
- 4) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary items.
- 5) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each and accordingly, the number of equity shares of the Company stands at 7,55,50,000 on the date of sub-division.
- 6) During the quarter, the company has allotted 26,750 equity shares of Rs 2 each under the Employee Stock Option Scheme 2015 and the total number of equity shares stands at 7,55,76,750.
- 7) The Company has invested a sum of USD 11,544 in its Wholly owned subsidiary company in Hongkong (namely Caplin Point Far East Limited) which has commenced the business operations during the current year.
The Company has also invested USD 40,000 in a subsidiary in Colombia (namely Caplin Point Laboratories Colombia SAS) which is yet to commence the business.
- 8) Figures for the current financial year are for the 12 months ended 31st March 2017 as against the 9 months period for the previous financial year ended 31st March 2016 and hence figures are not comparable.
- 9) Indian Accounting Standard (Ind AS) will be applicable from 1.4.2017. The company accordingly will be adopting the same w.e.f:1.4.2017
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director

Place : Chennai
Date : 10.05.2017





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNASAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL RESULTS OF CAPLIN POINT LABORATORIES LIMITED, CHENNAI FOR QUARTER ENDED MARCH 31 2017 AND FINANCIAL YEAR ENDED MARCH 31, 2017.

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED

1. We have audited the accompanying statements of Consolidated Financial Results of Caplin Point Laboratories Limited "the Holding Company" and its subsidiaries for the quarter ended March 31, 2017 and Financial Year ended March 31, 2017 (" the statement") being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement which is the responsibility of the Holding company's management and approval by the Board of Directors, has been prepared on the basis of the related Consolidated Financial Statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.
2. We conducted our audit in accordance with the auditing standards issued by the Institute of Chartered Accounts of India. . Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the statements. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant estimates made by management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
3. We did not audit the financial statements of two of the subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs 4188.79 Lakhs as at 31 st March 2017, total revenues of Rs 4850.34 Lakhs, total net profit after tax Rs 2518.26 Lakhs for the year ended on that date, as considered in the consolidated financial results. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion, on the statements, insofar as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.
4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other auditors referred to in paragraph 3 above, the statement:
 - i. includes the results of entities as given below:
 - a. Argus Salud Pharma LLP
 - b. Caplin Point Far East Limited
 - c. Caplin Point Laboratories Colombia SAS



ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

iii. gives a true and fair view of the consolidated Profit and other financial information for the quarter ended 31/03/2017 and the Financial Year ended March 31,2017

For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 004915S /S200036

B. Ramakrishnan

B.Ramakrishnan
Partner
(Membership No. 201023)



Place: Chennai

Date: 10/05/2017

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2017

Part I	Particulars	Quarter Ended			Year to date	9 Months period and Financial Year ended
		31.03.2017 (1) (Audited)	31.12.2016 (2) (Unaudited)	31.03.2016 (3) (Audited)	31.03.2017 (4) (Audited)	31.03.2016 (5) (Audited)
		Rs. In Lakhs				
1	Income					
	a. Net Sales/ income from operations (Net of Excise Duty)	11,805.71	10,279.04	8,190.97	40,164.85	23,872.17
	b. Foreign Exchange Fluctuation Gain	246.70	65.90	-	344.89	-
	c. Total	12,052.41	10,344.94	8,190.97	40,509.74	23,872.17
2	Expenditure					
	a. Cost of materials consumed	1,689.33	1,338.97	2,036.15	6,477.70	4,408.33
	b. Purchase of Stock-in-Trade	3,175.42	2,985.06	2,423.71	11,941.57	7,776.16
	c. Change in inventories of Finished Goods, work in progress and stock in trade	201.38	(136.88)	(378.15)	73.62	(68.04)
	d. Employees benefit expenses	795.11	852.33	710.82	2,988.00	1,846.68
	e. Depreciation & Amortisation Expenses	499.10	298.05	260.53	1,329.84	747.78
	f. Foreign Exchange Fluctuation Loss	-	-	31.11	-	293.36
	g. Other Expenditure	1,608.89	2,079.12	1,311.38	6,146.67	3,217.64
	h. Total Expenses	7,969.23	7,416.65	6,395.55	28,957.38	18,221.91
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	4,083.18	2,928.29	1,795.41	11,552.35	5,650.26
4	Other Income	181.40	153.83	154.21	638.59	365.96
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	4,264.58	3,082.11	1,949.62	12,190.95	6,016.22
6	Finance cost	3.47	1.84	2.92	12.75	11.02
7	Profit(+)/Loss(-) before Tax (5-6)	4,261.11	3,080.28	1,946.71	12,178.20	6,005.20
8	Provision for Taxation	716.72	575.46	446.94	2,255.70	1,430.61
	Provision for Taxation - earlier years					-
	Deferred Tax Provision	649.50	112.92	207.90	752.54	264.11
	Mat Credit Entitlement	(434.95)		(266.44)	(434.95)	(266.44)
9	Net Profit(+)/Loss(-) for the period (7-8)	3,329.84	2,391.90	1,558.31	9,604.90	4,576.92
10	Minority Interest	(10.95)	2.39	0.14	(10.95)	0.43
11	Net Profit(+)/Loss(-) for the period after minority interest (9-10)	3,340.79	2,389.51	1,558.17	9,615.85	4,576.49
12	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs Rs 2/- each wef 20 Oct 2016)	1,511.53	1,511.00	1,511.00	1,511.53	1,511.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				20,534.79	10,929.39
14	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 10/- per Equity share (prior to sub division of shares)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)			10.31		30.28
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)			10.31		30.28
	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 2/- per Equity share (post sub division of shares)					
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	4.42	3.16	2.06	12.72	6.05
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	4.42	3.16	2.06	12.72	6.05



Signature

Part II		Select information for the quarter ended 31st March 2017		
		Mar 2017	Dec 2016	Mar 2016
A	PARTICULARS OF SHARE HOLDING			
15	Public Shareholding			
	- Number of Shares	23382985	23356235	4863247
	- Percentage of Shareholding	30.94%	30.91%	32.19%
16	Promoters and promoter group Shareholding			
	a) Pledged/Encumbered			
	- Number of Shares	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)			
	- Percentage of shares (as a % of the total share capital of the company)			
	b) Non-encumbered			
	- Number of Shares	52193765	52193765	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	69.06%	69.09%	67.81%

B	Particulars	3 months ended 31-03-2017
	INVESTOR COMPLAINTS	
		Nos
	Pending at the beginning of the quarter	4
	Received during the quarter	164
	Disposed of during the quarter	166
	Remaining unresolved at the end of the quarter	2



Signature

STATEMENT OF ASSETS AND LIABILITIES

Particulars	CONSOLIDATED	
	As at 31/03/2017	As at 31-03-2016
	Rs. In lakhs	Rs. In lakhs
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share Capital	1,511.53	1,511.00
Reserves & Surplus	20,908.17	11,302.77
TOTAL SHARE HOLDERS FUNDS	22,419.70	12,813.77
Minority Interest	36.22	27.09
Non-Current Liabilities		
Long-Term Borrowings	47.51	73.08
Deferred Tax Liabilities (Net)	1,886.00	1,133.46
Long-Term Provisions	98.19	162.80
Total Non Current Assets	2,031.70	1,369.34
Current Liabilities		
Trade Payables	7,865.43	5,570.81
Other Current Liabilities	3,308.71	6,038.99
Short-Term Provisions	171.56	894.43
Total Current Liabilities	11,345.70	12,504.23
TOTAL	35,833.32	26,714.43
ASSETS		
Non-Current Assets		
Fixed Assets		
(i) Tangible Assets	15,046.06	14,362.85
(ii) Intangible Assets	137.22	60.22
(iii) Capital Work-in-Progress	341.52	23.20
Non-Current Investments	1,314.10	44.10
Long-Term Loans and Advances	841.20	370.77
Ttal Non Current Assets	17,680.10	14,861.14
Current Assets		
Current Investment	420.00	-
Inventories	2,229.49	1,881.49
Trade Receivables	3,302.48	794.53
Cash and Cash Equivalents	9,307.48	6,810.18
Short-Term Loans and Advances	2,630.75	2,114.96
Other Current Assets	263.02	252.12
Total Current Assets	18,153.22	11,853.29
Total	35,833.32	26,714.43



Lakshmi

Notes :

- 1) The Financial results of the company for the Year ended 31-03-2017 which have been audited by the statutory auditors have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 10-05-2017.
- 2) The Board of Directors at their meeting held on 10-05-2017, had recommended a final dividend of 75%, i.e Rs 1.50 paise per equity share of Rs 2/- each.
- 3) The consolidated financial results of the company and its subsidiaries have been prepared as per Accounting Standard 21 on Consolidated Financial Statements.
- 4) The Figures for the Quarter Ended 31 March 2017 are balancing figures between the audited figures in respect of the full financial year and the year-to-date figures upto the third Quarter of the Financial year.
- 5) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each and accordingly, the number of equity shares of the Company stands at 7,55,50,000 on the date of sub-division.
- 6) During the quarter, the company has allotted 26,750 equity shares of Rs 2 each under the Employee Stock Option Scheme 2015 and the total number of equity shares stands at 7,55,76,750.
- 7) Figures for the current financial year are for the 12 months ended 31st March 2017 as against the 9 months period for the previous financial year ended 31st March 2016 and hence figures are not comparable.
- 8) The Company has invested USD 11,544 in Wholly owned subsidiary in Hongkong (namely Caplin Point Far East Limited) which has commenced business operations during the current year.
The Company has also invested USD 40,000 in a subsidiary in Colombia (namely Caplin Point Laboratories Colombia SAS). The business operations is yet to commence.
- 9) Indian Accounting Standard (Ind AS) will be applicable from 1.4.2017. The company accordingly will be adopting the same w.e.f:1.4.2017
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.

Dr. Sridhar Ganesan
Managing Director

Place : Chennai

Date : 10.05.2017





CAPLIN POINT
LABORATORIES LTD.

CIN : L24231TN1990PLC019053

Regd. Off. : "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905
Fax : +91 44 28154952 E-mail : info@caplinpoint.net Website : www.caplinpoint.net

MAY 10, 2017

DECLARATION PURSUANT TO REGULATION 33(3) (D) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015

I, D Muralidharan, Chief Financial Officer, hereby declare that the Statutory Auditors of the Company, M/s. CNGSN & Associates LLP, Chartered Accountants, (Firm Registration No : 49155/S200036) have issued unmodified opinion on Standalone and Consolidated Audited Financial Results of the Company for the financial year ended March 31,2017.

D MURALIDHARAN
CHIEF FINANCIAL OFFICER



Unit I : No: 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: +91 413 2674046 / 4047

Unit II : No.19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District. Pincode - 601 201. Ph.: +91 44 27900901

Unit III : KHASRA No.435,Village Suraj Majra, N.H. No.21,Baddi, Teh. Nalagarh, District Solan, Himachal Pradesh - 173205. Ph.: +91 1795 245512

Unit IV: Survey No.: 895 & 897, Guruvarakandigai, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District, Pincode - 601 201.

Ph.: +9197884 59333/69333